{"entity":{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","aka":[],"tldr":"When an oncologist opens the order screen to prescribe a new line of treatment, the record would show the trials this patient may fit, with the nearest open site and a one-click referral.","summary":"Eligibility criteria are encoded in a structured, computable form (mCODE/FHIR profiles for stage, biomarkers, prior lines, performance status) and matched against the patient's record inside the EHR order-set workflow, not in a separate portal. Alerts fire only at decision points (new line of therapy, progression documented) to avoid fatigue. Several AI matching tools exist; the missing piece is embedding at the point of decision with a referral action.","asOf":"2026-09-08","links":[{"label":"mCODE (minimal Common Oncology Data Elements)","url":"https://mcodeinitiative.org/"},{"label":"HL7 FHIR","url":"https://hl7.org/fhir/"}],"tags":[],"related":["clinicaltrials-gov"],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":["tempus","cancer-commons"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-enrolment","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Point-of-decision matching will double the proportion of eligible patients who are offered a trial in participating practices, measured by chart review, compared with practices using the same matching tool in a stand-alone portal.","rationale":"Most patients are never told about a trial; the failure is at the moment of prescribing, when the physician's attention is on the standard option. Decision-support that appears at that moment changes prescribing behaviour in other fields (antibiotic stewardship, anticoagulation).","test":"Cluster-randomised trial across 20 community oncology practices sharing one EHR vendor: embedded alert versus portal-only, primary outcome trial offer rate documented in notes, secondary enrolment rate.","maturity":"early-clinical","actor":"engineering","cost":"medium","horizonYears":3},"route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/","neighbours":{"collection":[{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/"}],"technology":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/"}],"company":[{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/"},{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/"}],"bottleneck":[{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}]}}